anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to compositions comprising a derivative of 5 - aminolevulinic acid (5-ALA), e.g. an ester of 5-ALA or a skin compatible salt thereof. Further, the invention relates to use of such compositions in methods of cosmetic or therapeutic treatment, particularly in methods of improving or otherwise enhancing the appearance of the skin. The compositions comprise 2% by weight or less of a derivative of 5-ALA, 70% by weight or more of water, 2-25% by weight of at least one liquid carrier and one or more emulsifiers. A container comprises a first compartment comprising a derivative of 5-ALA and at least one liquid carrier and a second compartment comprising water, one or more emulsifiers and optionally at least one liquid carrier. The composition is obtained by mixing the contents of the two compartments.
Preterm birth is the largest contributor to neonatal morbidity and is often associated with chorioamnionitis, defined as inflammation/infection of the fetal membranes (FMs). Chorioamnionitis is characterised by neutrophil infiltration of the FMs and is associated with elevated levels of the neutrophil chemoattractant, interleukin (IL)-8 and the proinflammatory cytokine, IL-1β. While FMs can respond to infections through innate immune sensors, such as toll-like receptors (TLRs), the downstream mechanisms by which chorioamnionitis arises are not fully understood. A novel group of non-classical microRNAs (miR-21a, miR-29a, miR-146a-3p, Let-7b) function as endogenous danger signals by activating the ssRNA viral sensors TLR7 and TLR8. In this study, the pro-inflammatory roles of TLR7/TLR8-activating miRs were examined as mediators of FM inflammation in response to bacterial lipopolysaccharide (LPS) using an in vitro human FM explant system, an in vivo mouse model of pregnancy, and human clinical samples. Following LPS exposure, miR-146a-3p was significantly increased in both human FM explants and wild-type mouse FMs. Expression of miR-146a-3p was also significantly elevated in FMs from women with preterm birth and chorioamnionitis. FM IL-8 and inflammasome-mediated IL-1β production in response to LPS was dependent on miR-146a-3p and TLR8 downstream of TLR4 activation. In wild-type mice, LPS exposure increased FM IL-8 and IL-1β production and induced preterm birth. In TLR7-/-/TLR8-/- mice, LPS exposure was able to initiate but not sustain preterm birth, and FM inflammation was reduced. Together, we demonstrate a novel signalling mechanism at the maternal-fetal interface in which TLR8-activating miR-146a-3p acts as an intermediate danger signal to drive FM inflammasome-dependent and -independent mechanisms of inflammation and, thus, may play a role in chorioamnionitis and subsequent preterm birth.
The present invention is directed to modified integrin proteins and methods and compositions using integrin-based therapeutics. In one embodiment, the modified integrins demonstrate increased occurrence or duration of the E-H+ integrin protein conformation. In another embodiment, the compounds of the present invention stabilize E-H+ integrin protein conformation, increasing the occurrence or duration of the E-H+ integrin protein conformation. In another embodiment, the compounds of the present invention inhibit binding of a ligand of an integrin. In yet a further embodiment, the present compounds increase cis binding of the integrin or signaling based thereon. The present compounds decrease the occurrence or duration of trans binding of the integrin or signaling based thereon. The modified integrins and compounds described herein may be used in methods of treating immune modulated diseases or inflammatory diseases or conditions.
PROBLEM TO BE SOLVED: To obtain an emulsified compsn. having satisfactory aging stability of the emulsified state without using a surfactant by incorporating an alkyl modified carboxyvinyl polymer and PVA, its deriv. or polyvinylpyrrolidone. SOLUTION: The stability of an emulsified compsn. over a long period of time is improved by incorporating PVA or its deriv. such as polyvinyl acetate and/or polyvinylpyrrolidone and an alkyl modified carboxyvinyl polymer such as an acrylic acid-alkyl methacrylate copolymer preferably by 0.05-1wt.% and 0.05-5wt.%, respectively. Oil is further incorporated by 1-50wt.%.
Investigating VIP236 in a dose escalation cohort in subjects with advanced solid tumor cancer. Dosing occurs on D1 and D15 of each 28-day cycle.
Transcranial direct current stimulation (tDCS) device using 50x70 mm electrodes that has the anodal electrode placed contralateral to most prominent ocular pain or, in the case of bilateral pain symptoms, contralateral to the dominant hand between EEG coordinates C3/C5 for left hemisphere and C4/C6 for right hemisphere (corresponding to S1 and M1 of the eye), and the cathode placed on the patient's upper arm. A current peaking at 3mA will ramp up for 20 secs and be delivered for a total of 20 minutes, thereafter, ramping down for 20s. An impedance value under 15 ohms is required at all times to ensure patient comfort and safety.
Subjects will collect spectral raman data on P0.2 four times a day for 30 days distributed over a time period of 40 days. Spectral data will be compared to standard BG measurements. The number of optical sessions performed each time measurements are done are increased compared to the investigation's second arm.
Acetaminophen

There have been postmarketing reports of hypersensitivity and anaphylaxis associated with the use of acetaminophen. Clinical signs included swelling of the face, mouth, and throat, respiratory distress, urticaria, rash, pruritus, and vomiting. There were infrequent reports of life-threatening anaphylaxis requiring emergency medical attention. Instruct patients to discontinue COMBOGESIC immediately and seek emergency medical care if they experience these symptoms. Do not prescribe COMBOGESIC for patients with acetaminophen allergy [see Contraindications (4)].

Ibuprofen

NSAIDs, including the ibuprofen in COMBOGESIC, has been associated with anaphylactic reactions in patients with and without known hypersensitivity to ibuprofen and in patients with aspirin-sensitive asthma. Instruct patients to discontinue COMBOGESIC immediately and seek emergency medical care if they experience these symptoms. Do not prescribe COMBOGESIC for patients with ibuprofen or NSAID allergy [see Contraindications (4) and Warnings and Precautions (5.8)].
PURPOSE: 20% of patients with mechanical ventilation (MV) have a prolonged, complex weaning process, often experiencing a condition of ICU-acquired weakness (ICUAW), with a severe decrease in muscle function and restricted long-term prognosis. We aimed to analyze a protocolized, systematic approach of physiotherapy in prolonged weaning patients and hypothesized that the duration of weaning from MV would be shortened.
METHODS: ICU patients with prolonged weaning were included before (group 1) and after (group 2) introduction of a quality control measure of a structured and protocolized physiotherapy program. Primary endpoint was the tested dynamometric handgrip strength and the Surgical Intensive Care Unit Optimal Mobilization Score (SOMS). Secondary endpoints were weaning success rate, ventilator-free days, hospital mortality, the prevalence of ICUAW, infections and delirium.
RESULTS: 106 patients were included. Both the SOMS and the handgrip test were significantly improved after introducing the program. Despite no differences in weaning success rates at discharge, the total length of MV was significantly shorter in group 2, which also had lower prevalence of infection and higher probability of survival.
CONCLUSIONS: Protocolized, systematic physiotherapy resulted in an improvement of the clinical outcome in patients with prolonged weaning. Results were objectifiable with the SOMS and the handgrip test.
Foltamin™ Tablets are supplied as round, light yellow tablets with one side scored, the other side plain and dispensed in child-resistant bottles of 30 tablets (NDC 59088-200-54*). 

* This product is a prescription-folate with or without other dietary ingredients that – due to increased folate levels (AUG 2, 1973 FR 20750), requires an Rx on the label because of increased risk associated with masking of B 12 deficiency (pernicious anemia). Based on our assessment of the risk of obscuring pernicious anemia, this product requires licensed medical supervision, an Rx status, and a National Drug Code (NDC) or similarly-formatted product code, as required by pedigree reporting requirements and supply-chain control as well as in some cases, for insurance-reimbursement applications. 

All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product. This product may be administered only under a physician’s supervision. There are no implied or explicit claims on therapeutic equivalence
Removing the overexpressed TNF-α by hemoperfusion positively affects clinical treatments for diseases such as autoimmune disease and sepsis. However, clearance ratios of adsorbents targeting TNF-α were limited by the extremely low concentration of TNF-α (mostly <1000 ng/L in sepsis) and hydrophobic interactions. In this work, biparatopic nanobodies (NbC21) with a high affinity of 19.9 pM, which bind to two distinct sites of TNF-α, were constructed as high-affinity ligands for the immunosorbent. The theoretical maximum adsorption capacity estimated from the Langmuir isotherm was up to 18.22 mg/g gel. The prepared immunosorbent (NbC21-sorbent) had an outstanding TNF-α clearance ratio of approximately 96% during the dynamic adsorption test, with a sorbent-to-serum ratio of 1:1000. Additionally, it demonstrated favorable hemocompatibility and a prolonged storage capability. The results indicated that the biparatopic nanobody immunosorbent exhibited significant potential for clinical applications as it met the stringent criteria for both efficacy and safety.
Buprenorphine/naloxone via specialist center (B-SC) x 3 months followed by B-PO x 7 months. The specialist center in this trial will be a methadone clinic.
<P>PROBLEM TO BE SOLVED: To solve problems that carbohydrate-mediated interactions are weak and polyvalent and are correspondingly difficult to detect, and, there is no satisfactory tool for detecting the interactions in the technical field.  <P>SOLUTION: Materials and methods for studying and modulating the interactions of carbohydrate-containing moieties with other chemical species are described, in particular, small particles, e.g. clusters of metal or semiconductor atoms, which can be employed as a substrate for immobilizing a plurality of ligands comprising carbohydrate groups. Further, the nanoparticles can be used for investigating the carbohydrate-mediated interactions, e.g. the interactions with other carbohydrates or proteins, and as therapeutic agents, and diagnostic reagents.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The present invention describes using fluorous chemistry in n.c.a. nucleophilic aromatic 18F-fluorination reactions by using perfluoro-aryliodonium salts as a precursor for aromatic nucleophilic substitution using a [18F] F- anion to displace a suitable leaving group from an electron deficient benzene ring. The results showed that using perfluoro-aryliodonium salts as a precursor is a suitable leaving group for n. c. a. nucleophilic aromatic 18F-fluorination in synthesis.. The PT-precursor seems to be quite stable. In an attempt to purify the crude 18F-labeled product using fluorous solid phase extraction (F-SPE), the radio labeled impurities decreased significantly. Thus, it is possible to use this PT methodology to simplify and speed up purification methods.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to ophthalmology, and can be used for differentiated treatment of corneal erosions and ulcers. For this purpose, a product of platelet-rich autoplasma (PRP) is used. For corneal erosions and ulcers with depth of 100 mcm and less, PRP lysate is used, obtained from platelet-rich plasma containing platelet count of not less than 1,000*109cells/l, with a proportion of functionally adequate thrombocytes of not less than 38 %. In case of erosions, PRP lysate is instilled in dose of 1 drop 3 times a day until complete healing. In case of ulcer depth of 100 mcm and less — subconjunctival injections once a day in dose of 0.5 ml, in total 3 injections. In case of corneal ulcer with depth of more than 100 mcm — covering of cornea with thrombofibrin clot fixed by amniotic membrane, combined with subconjunctival introduction along limb in 4 quadrants of autologous serum in total volume of 1 ml. Tarsorrhaphy is performed.EFFECT: invention provides effective treatment of the cornea depending on the nature and depth of its damage with accelerated healing of the injured surface, formation of opacity of lower intensity with deep injuries, reduction of recurrence rate.1 cl, 3 dwg, 3 ex
A method for the complex treatment of the dentition defects provides for the use of the dental implants and regenerative technologies. The method comprises the clinical examination, the planning of the surgical protocol for installation of the implants and orthopedic construction of the dental prosthesis with abutment onto the implants. In the course of the surgery, autologic plasma enriched with platelets and PRGF is obtained as gel, clot and biological fibrin membrane. The trapezium-shaped cut is performed under infiltration anesthesia. The mucous-periosteal flap is separated and the bone bed is formed. The bone canal is irrigated and the implant is moistened with PRGF gel. The implant is set up. The bone defect around the implant is filled with autograft representing the mixture of the ground autologic bone in PRGF clot. The implant is covered with biological fibrin membrane, the flap is juxtaposed and sutured.
PURPOSE:To provide an inexpensive, readily available humectant, comprising as the main component, a partial degradation product with a specific weight- average molecular weight which can be obtained by degrading grain protein such as wheat gluten or soybean protein through a combination of degradation treatments using, respectively, an alkali and acid. CONSTITUTION:The objective humectant consisting mainly of a partial degradation product 3000-110000 (pref. 20000-100000) in weight-average molecular weight which can be obtained by degradation treatment of grain protein such as wheat gluten, corn gluten or soybean protein. It is suggested that the degradation treatment be performed through a combination of (A) a treatment using an alkali and (B) at least one of treatments using, respectively, an acid, enzyme, reducing agent and oxidizing agent (pref. alkali-acid combination). The present humectant can suitably be formulated in cosmetics, shampoos, rinses, foods, detergents for tablewares, etc.
A system ingests the purchases of a user at various retail outlets and are analyzed to characterize a user's taste profile as well as the complexity and effort of meals prepared by the user. A meal plan including the preparation of recipes corresponding to the user's taste, complexity, and effort profiles. Meal plan media including instructions for preparing the meals of the meal plan are provided. Interactions or lack thereof and the date of interactions are monitored and analyzed to determine whether a meal was executed and the date of execution. A weekly schedule profile of the user is developed based on the complexity and effort scores of meals and the determination of whether the meals are or are not executed. Subsequent meal plans are generated based on the schedule profile and the taste profile updated per determinations of which meals are executed.
The means is used for the treatment of dermatoses such as psoriasis, neurodermite, trophic ulcers, eczema, acne and other disruptions of the skin integrity. It has antiphlogistic, regenerative and trophic effect normalizing metabolism in dermal and epithelial tissues. It comprises an extract of medicamentous plants Calendula officinalis and Hypericum perforatum in ratio 1:1 to 3:1 wt.%. The extract comprises low molecular peptides and free amino acids in sum from 0.6 to 6% of the dry extract mass, in particular histidine, cystine, alanine, valine, leucine, isoleucine, phenylalanine, glycine, lysine, tyrosine, glutamine, aspargine, methionine, unsaturated fatty acids from 1 to 10%, in particular linolic, linoleic and oleinic acid; vitamins in sum from 1.0 to 6%, including retinoids from 0.6 to 3%; and minerals and microelements from 1 to 6%. The extract is aqueous and/or with organic solvent, and/or oily in ratio between the medicamentous plants and the extragent from 1:5 to 1:25. The quantitative content of the above biologically active substances depends on the type of extragent used.
BACKGROUND: Genetic, lifestyle, reproductive, and anthropometric factors are associated with the risk of developing breast cancer. However, it is not yet known whether polygenic risk score (PRS) and absolute risk based on a combination of risk factors are associated with the risk of progression of breast cancer. This study aims to estimate the distribution of sojourn time (pre-clinical screen-detectable period) and mammographic sensitivity by absolute breast cancer risk derived from polygenic profile and the other risk factors.
METHODS: The authors used data from a population-based case-control study. Six categories of 10-year absolute risk based on different combinations of risk factors were derived using the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm. Women were classified into low, medium, and high-risk groups. The authors constructed a continuous-time multistate model. To calculate the sojourn time, they simulated the trajectories of subjects through the disease states.
RESULTS: There was little difference in sojourn time with a large overlap in the 95% confidence interval (CI) between the risk groups across the six risk categories and PRS studied. However, the age of entry into the screen-detectable state varied by risk category, with the mean age of entry of 53.4 years (95% CI, 52.2-54.1) and 57.0 years (95% CI, 55.1-57.7) in the high-risk and low-risk women, respectively.
CONCLUSION: In risk-stratified breast screening, the age at the start of screening, but not necessarily the frequency of screening, should be tailored to a woman's risk level. The optimal risk-stratified screening strategy that would improve the benefit-to-harm balance and the cost-effectiveness of the screening programs needs to be studied.
This study will examine the pain-relieving effects of a transcutaneous electrical nerve stimulator device called a Quell for persons with multiple chronic overlapping pain conditions. Participants will attend two quantitative sensory testing visits in order to determine their level of pain sensitivity, one at the beginning of the study and the second at the 3-month Follow-up session. Participants will be asked to test out the Quell device to check for sensation tolerance, and will then be randomized into one of the two treatment groups: the High Intensity Quell group or the Low Intensity Quell group. Participants will be asked to wear the device for at least 3 hours every day and to complete daily assessments, along with a total of three sets of questionnaires: one at the start of the study, the second 6 weeks from the date of consent, and the third 3 months after the date of consent. A member of the research staff will call participants once a week for a brief phone interview throughout the study. Participants will be in this study for 3 months.
OBJECTIVE: We studied blink reflex (BR) and BR excitability recovery (BRER) in patients with hemifacial spasm (HFS) exhibiting different abnormal discharge patterns. We hypothesized that patients with groups of clonic or tonic burst activities appear later in the disease course and may have more excitability of the BR circuit at the brainstem compared to patients with isolated twitchings, which occur earlier.
METHODS: We included 124 patients with botulinum toxin-naive HFS (mean age 50.6 ± 13.3 years) and 40 healthy subjects. We performed surface polymyography on facial muscles in patients and classified them according to the abnormal discharge pattern: isolated discharges, grouped bursts forming random sequences, tonic spasms, and a combination of these activities. Then, we recorded BR and BRER at 200, 600, and 1000 ms interstimulus intervals. We compared disease duration, R1 and R2 latencies, R2 area-under-the-curve (AUC), and BRER% (i) between healthy subjects and patients and (ii) among groups of patients with different abnormal discharge patterns.
RESULTS: There were isolated discharges in 28 patients, grouped bursts forming random sequences in 42, and continuous muscle activity with tonic spasms in one. The remaining patients had combinations. Mean R1 and R2 latencies were significantly longer, and mean R2 AUC was significantly higher on the symptomatic side of patients compared to healthy subjects. The mean BRER was enhanced on both sides in patients than in healthy subjects (p < 0.001). However, it was similar among patient groups with different abnormal discharge patterns (p > 0.05). The mean disease duration in patients with isolated discharges was shorter (3.3 ± 2.0 years) than those with grouped bursts or tonic spasms (p = 0.002; Kruskal-Wallis test).
CONCLUSION: Our study observed that excitability at the brainstem was similar in HFS patients with different abnormal discharge patterns, suggesting that the difference in discharge patterns in HFS may be due to a reason other than the difference in BR excitability.
A steroidal sapogenin, e.g. hecogenin, is obtained from plant material containing sapogenin-yielding material, e.g. the waste from decorticated sisal leaves, by a process in which the juice is expressed to separate the sapogenin-yielding material therefrom. Subsequently the juice is subjected to acid hydrolysis, e.g. with sulphuric acid, to provide water-insoluble hecogenin which is recovered from the hydrolysate by collection on an adsorbent substance, such as activated charcoal, and which is extracted with a solvent, e.g. ether, isopropyl ether, ethyl acetate benzene or carbon tetrachloride.  The hecogenin is obtained therefrom by fractional crystallization.  Specification 702,072 is referred to.
This application relates to a drug delivery composition comprising a nonpolymeric, solidified matrix and a drug dispersed in the matrix. The matrix material comprises an organic metal salt or silica or titania, or a combination thereof. In one embodiment the drug is substantially uniformly dispersed in the matrix in a particulate form. The matrix material encapsulates the drug particles and controls its release in vivo. Optionally a biodegradable lipid layer may be applied to the matrix. The drug delivery composition may be applied to the surface of a medical device, such as a cardiovascular stent, or may be formulated as a pharmaceutical preparation suitable for other means of administration. Methods of forming the composition are described which enable in situ encapsulation of both water-insoluble and water-soluble drugs.